Skip to content
HowShorted

FILANA THERAPEUTICS, INC. short interest in 2022

In 2022, FILANA THERAPEUTICS, INC.'s disclosed short interest ran from 32.46% of shares outstanding on 14 Jan 2022 to 21.70% on 30 Dec 2022, a change of -10.76 percentage points. The year's high was 33.99% on 31 Jan 2022 and its low 21.70% on 30 Dec 2022, averaging 27.47% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 13.21 days on 15 Jul 2022. Full history: FILANA THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for FILANA THERAPEUTICS, INC. in 2022

2022 in figures

Start of year
32.46% (14 Jan 2022)
End of year
21.70% (30 Dec 2022)
Change
-10.76 pp
High
33.99% (31 Jan 2022)
Low
21.70% (30 Dec 2022)
Average
27.47%
Highest days to cover
13.21 (15 Jul 2022)
SEC filings marked
8

Every report in 2022

FILANA THERAPEUTICS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202232.46%5.09
31 Jan 202233.99%7.32
15 Feb 202229.86%5.24
28 Feb 202228.24%10.15results (8-K)
15 Mar 202227.31%10.6010-K filed
31 Mar 202226.67%10.14
14 Apr 202228.64%5.15
29 Apr 202229.37%4.09
13 May 202229.56%10.0710-Q filed, results (8-K)
31 May 202228.77%6.42
15 Jun 202227.37%11.01
30 Jun 202225.97%12.48
15 Jul 202225.40%13.21
29 Jul 202228.52%4.80
15 Aug 202230.06%5.97results (8-K), 10-Q filed
31 Aug 202231.38%1.87
15 Sep 202231.31%6.55
30 Sep 202226.87%1.55
14 Oct 202224.03%5.58
31 Oct 202223.38%11.98
15 Nov 202223.28%6.2010-Q filed, results (8-K)
30 Nov 202223.29%7.01
15 Dec 202221.96%6.79
30 Dec 202221.70%6.92

See also: FILANA THERAPEUTICS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.